Evidence map›Paper›PMID 37318583›Full record

ReviewUrologie (Heidelberg, Germany)2023

[New tracers and combinations in radioligand therapy for prostate cancer].

Robert Tauber, Lukas Lunger, Matthias Eiber, Jürgen E Gschwend

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Urologie (Heidelberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Robert TauberKlinik und Poliklinik für Urologie, Universitätsklinikum rechts der Isar der Technischen Universität München, Ismaninger Str. 22, 81675, München, Deutschland. robert.tauber@tum.de.
Lukas LungerKlinik und Poliklinik für Urologie, Universitätsklinikum rechts der Isar der Technischen Universität München, Ismaninger Str. 22, 81675, München, Deutschland.
Matthias EiberKlinik und Poliklinik für Nuklearmedizin, Universitätsklinikum rechts der Isar der Technischen Universität München, München, Deutschland.
Jürgen E GschwendKlinik und Poliklinik für Urologie, Universitätsklinikum rechts der Isar der Technischen Universität München, Ismaninger Str. 22, 81675, München, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

objectivesWhat are new or emerging developments in radioligand therapy for prostate cancer? MATERIALS AND

methodsA review of the current literature was performed.

resultsThe further development of radioligand therapy for prostate cancer is currently taking place primarily in the following areas: application in earlier stages of the disease, use of alternative isotopes, development and use of new ligands, search for new target structures and combination with other forms of therapy.

conclusionsRadioligand therapy has become an integral part of the therapy algorithm in the treatment of metastatic, castration-resistant prostate cancer. Application in earlier stages of the disease is foreseeable. In the future, new ligands, alternative isotopes, new targets or combination therapies may increase efficacy and reduce toxicity.

Indexed as

Prostatic Neoplasms, Castration-ResistantHumansLigandsMaleProstate-Specific AntigenRadiopharmaceuticalsTreatment OutcomeLigandsProstate-Specific AntigenRadiopharmaceuticals177LutetiummCRPCProstate-specific membrane antigenRadionuclide therapyTargeted therapy

Identifiers

PMID37318583

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.